ABCA1, ABCA7, and LRP1 in Brain Cholesterol Efflux and Clearance

Because the human brain contains ~23% of total body unesterified cholesterol (~15–20 mg/g wet weight, sequestered within oligodendrocyte myelin sheaths and neuronal synaptic membranes) yet is isolated from circulating peripheral lipoproteins by the tight junctions of the blood–brain barrier (BBB), central nervous system (CNS) lipid homeostasis relies on an autonomous intercellular transport cycle mediated by ATP-Binding Cassette Subfamily A Member 1 (ABCA1 on Chr9q31.1), Member 7 (ABCA7 on subtelomeric Chr19p13.3), and Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1 on Chr12q13.3). Inside the brain parenchyma, astrocytes synthesize cholesterol de novo via the mevalonate pathway and utilize ABCA1 (together with ABCG1) to pump unesterified cholesterol and choline phospholipids onto lipid-poor Apolipoprotein E (APOE), generating discoidal high-density lipoprotein (HDL)-like particles that are taken up by neurons and glia via LRP1 and related LDLR family receptors.

Simultaneously, the ABCA1–ABCA7–LRP1 axis governs the clearance and seeding of pathogenic amyloid-β (Aβ) and microtubule-associated protein tau (MAPT) in late-onset Alzheimer disease (LOAD). Well-lipidated APOE discs generated by ABCA1 bind soluble monomeric Aβ40 and Aβ42 with high affinity and facilitate proteolytic degradation or perivascular clearance, whereas ABCA7 maintains microglial phagocytic cup phospholipids and endolysosomal trafficking, and LRP1 functions as both the primary abluminal BBB transcytosis receptor exporting Aβ into peripheral blood and the neuronal cell-surface receptor mediating trans-synaptic tau propagation.

ABCA1 Alternating-Access Lateral-Gate Mechanism and Tangier Disease

ABCA1 (147.2 kb, 50 exons) encodes a 2,261-amino-acid (254-kDa) full-length transmembrane transporter organized into two symmetrical halves, each comprising a 6-transmembrane (6-TM) domain (TMD1 and TMD2), a large glycosylated extracellular domain (ECD1 and ECD2) stabilized by intramolecular disulfide bonds that encloses a continuous hydrophobic tunnel ~65 Å above the outer leaflet, a cytoplasmic nucleotide-binding domain (NBD1 and NBD2) containing canonical Walker A, Walker B, and ABC signature (LSGGQ) motifs that hydrolyze ATP, and a cytoplasmic regulatory domain (R1 and R2).

Cryo-electron microscopy (cryo-EM) reconstructions (3.1–4.1 Å resolution) demonstrate that unlike multidrug-resistance ABC exporters (ABCB1), which alternate between inward- and outward-facing V-shaped cavities, ABCA1 operates via a lateral-access phospholipid extraction and extrusion mechanism:

1. Inward Lateral Gate Opening (ATP-Unbound State): In the absence of nucleotide, TMD1 and TMD2 separate laterally toward the cytoplasmic and exoplasmic leaflets of the plasma membrane bilayer, allowing phosphatidylcholine, phosphatidylserine, and free cholesterol to diffuse sideways into a shallow positively charged pocket between TM1/TM2 and TM7/TM11.
2. ATP Binding, NBD Dimerization, and Hydrophobic Tunnel Extrusion: Binding of two ATP·Mg2+ molecules closes the cytoplasmic NBD1–NBD2 head-to-tail dimer, snapping TMD1 and TMD2 together (squeezing the inter-TMD lipid pocket) and pushing phospholipids upward into the hollow flame-shaped hydrophobic tunnel inside ECD1–ECD2, where lipid-free APOA1 (in periphery) or APOE (in brain) docks to accept nascent discoidal bilayers (10–12 nm hydrodynamic diameter).

In humans, biallelic loss-of-function mutations in ABCA1 cause Tangier disease (OMIM #205400), characterized by virtual absence of plasma HDL cholesterol (<5 mg/dL) and APOA1, hypercatabolism of unlipidated apolipoproteins, cholesteryl ester-laden foam-cell enlargement of palatine tonsils (orange tonsils), hepatosplenomegaly, and peripheral demyelinating neuropathy. In the brain, heterozygous loss-of-function variants—most notably ABCA1 Asn1800His (N1800H, rs2066715)—impair astrocytic APOE lipidation (leaving APOE4 in a self-aggregating hypolipidated state) and increase Alzheimer disease and cerebrovascular hemorrhage risk 3.5- to 4.1-fold.

ABCA7 Subtelomeric Architecture, Premature Termination Variants, and Intron 18 VNTR

Located only 1.04 Mb from the short-arm telomere of chromosome 19 (chr19:1,040,101–1,065,571), ABCA7 (25.6 kb, 47 exons) shares 54% amino acid sequence identity with ABCA1 (2,146 residues, 234 kDa), but exhibits a distinct expression profile and lipid substrate specificity. Whereas ABCA1 transcription is driven by oxysterol-activated LXR:RXR nuclear receptors, ABCA7 transcription is upregulated by Sterol Regulatory Element-Binding Protein 2 (SREBP2) when cellular sterol levels fall. Biochemically, ABCA7 exports choline phospholipids, sphingomyelin, and ceramides across microglial and neuronal membranes (with lower free-cholesterol efflux capacity than ABCA1), regulating endoplasmic reticulum stress, mitochondrial cardiolipin maintenance, and actin-dependent phagocytic cup formation around Aβ oligomers and apoptotic debris.

Human genetic sequencing across European and African ancestry cohorts establishes ABCA7 as one of the strongest loss-of-function risk genes for Alzheimer disease:

• Rare Premature Termination Variants (PTVs) and Cryptic Splice Sites: Nonsense, frameshift (such as the European founder deletion c.2126_2132del7, Glu709Alafs*86), and canonical splice-site variants occur in 1.5–2.2% of European LOAD cases (OR = 2.0–4.0). In African Americans, a 44-bp exonic deletion (rs142076058, p.Arg578Alafs*36) reaches ~7–8% carrier frequency in cases (OR ≈ 1.8–2.1). Although many ABCA7 PTVs trigger nonsense-mediated mRNA decay (NMD), partial rescue occurs via in-frame cryptic splicing that yields unstable, hypomorphic transporter isoforms.
• The Subtelomeric Intron 18 VNTR Expansion: Consistent with the high recombination and repeat instability of human subtelomeres, Intron 18 of ABCA7 (immediately downstream of the Exon 18 donor splice site) harbors a GC-rich variable number tandem repeat (VNTR) built from a 25-bp consensus motif ([GGGGCC/GGG]-like purine-rich tracts capable of folding into G-quadruplex secondary structures). Total repeat tract length varies across over an order of magnitude in the human population, ranging from 300 bp (~12 copies) to >10.7 kb (>420 copies). Long-read nanopore and Southern blot phasing demonstrate that pathogenic expansions >5.7 kb promote alternative splicing that skips Exon 19 (which encodes the critical Walker A nucleotide-binding loop of NBD1), conferring a 4.5-fold increase in Alzheimer disease risk (OR = 4.48) and accounting for the majority of the common GWAS signal (rs3752246 / rs4147929) at 19p13.3.

Structural Organization of the 600-kDa LRP1 Scavenger Receptor

Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1, also designated CD91 on Chr12q13.3) is a 4,544-amino-acid (600-kDa) multifunctional endocytic and signaling receptor cleaved in the trans-Golgi network by the proprotein convertase furin (between Arg3924 and Ser3925) into two non-covalently associated subunits:

1. The Extracellular 515-kDa Heavy α-Chain (3,905 residues): Contains four ligand-binding clusters (Clusters I, II, III, and IV) comprising 2, 8, 10, and 11 cysteine-rich complement-type repeats (CR domains, stabilized by three disulfide bonds and an octahedral Ca2+-coordination cage), separated by epidermal growth factor (EGF)-precursor homology domains and six-bladed YWTD β-propeller domains that fold back at acidic endosomal pH (<6.0) to displace bound ligands for lysosomal delivery.
2. The Transmembrane 85-kDa Light β-Chain (615 residues): Anchors LRP1 in the plasma membrane and contains a 100-residue cytoplasmic tail bearing two NPxY motifs (NPTY at Tyr4473 and NPVY at Tyr4507), one YxxL motif (YATL at Tyr4507/Leu4510), and two dileucine motifs. Unlike LDLR, whose endocytosis is driven by its NPxY motif (~150 s half-time), LRP1 constitutive clathrin-mediated endocytosis is driven primarily by its YxxL and dileucine motifs at an exceptionally rapid rate (t1/2 < 30 seconds).

Dual Role in Blood-Brain Barrier Aβ Export and Neuronal Tau Uptake

Within the central nervous system, LRP1 exerts opposing protective and pathogenic effects depending on cell type and disease stage:

• Protective Neurovascular and Astrocytic Clearance of Aβ: On the abluminal (brain-facing) membrane of brain capillary endothelial cells, LRP1 Cluster II and Cluster IV bind monomeric and oligomeric Aβ40 and Aβ42 directly (as well as APOE2/APOE3–Aβ and activated α2-macroglobulin–Aβ complexes), mediating rapid transcytosis across the BBB into systemic circulation (assisted by P-glycoprotein ABCB1 and PICALM-clathrin vesicles). With aging and in Alzheimer disease, endothelial LRP1 expression declines by 40–60%, whereas soluble LRP1 (sLRP1, shed in plasma as a peripheral sink binding 70–90% of circulating Aβ) becomes oxidatively modified, impairing brain-to-blood Aβ clearance. Crucially, whereas Aβ-free APOE2 and APOE3 clear via both LRP1 and VLDLR, APOE4–Aβ complexes redirect clearance from rapid VLDLR endocytosis to slower LRP1 pathways and compete with free Aβ for astrocytic LRP1 uptake.
• Pathogenic Neuronal Internalization and Propagation of Tau (MAPT): In 2020, CRISPR interference (CRISPRi) functional genomic screens revealed that neuronal LRP1 is the master cell-surface receptor controlling the endocytosis and trans-synaptic spread of pathogenic tau seeds. Specifically, lysine residues within the microtubule-binding repeat domain (MTBR, R1–R4) and flanking proline-rich region of tau bind electrostatically to CR repeats inside LRP1 Cluster II and Cluster IV in cooperation with cell-surface heparan sulfate proteoglycans (HSPGs). Conditional deletion of Lrp1 in mouse neurons reduces trans-neuronal tau propagation by >80%. Furthermore, APOE4 enhances LRP1-mediated tau internalization, whereas the protective APOE3-Christchurch (R136S) mutation alters the basic receptor-binding patch (residues 136–150), abrogating HSPG binding and competitively blocking tau uptake via LRP1.

How do LXR and RXR agonists upregulate ABCA1 to clear brain amyloid, and why did first-generation agonists cause hepatosteatosis?

Nuclear Liver X Receptors (LXRα/LXRβ) and Retinoid X Receptors (RXRα) bind direct-repeat (DR4) response elements in the ABCA1 and APOE promoters. Synthetic agonists (T0901317, GW3965, bexarotene) increase astrocytic ABCA1 expression 3- to 5-fold, generating fully lipidated APOE HDL discs that accelerate microglial Aβ degradation. However, systemic LXRα activation in the liver simultaneously induces SREBP-1c, driving hepatic de novo fatty-acid synthesis (FASN, SCD1) and severe hypertriglyceridemia, motivating CNS-selective ABCA1 inducers or direct CS-6253 ABCA1-agonist peptides.

Why is the ABCA7 Intron 18 VNTR invisible to standard short-read whole-exome sequencing?

Standard short-read sequencing (150-bp paired-end Illumina reads) cannot span repetitive GC-rich tracts exceeding the 300–500 bp library insert size, and PCR amplification fails across high-GC G-quadruplex-forming repeats (>70% GC) spanning 3 to 10 kb. Resolving the pathogenic >5.7 kb ABCA7 Intron 18 VNTR expansion requires amplification-free long-read sequencing (Oxford Nanopore or PacBio HiFi reads >15 kb) or Southern blot hybridization.

Why does LRP1 clear Aβ40 across the blood-brain barrier faster than Aβ42?

Surface plasmon resonance (SPR) binding kinetics show that Aβ40 binds LRP1 Cluster II and Cluster IV with higher affinity (Kd ≈ 0.6–1.2 nM) than Aβ42 (Kd ≈ 3.5–5.0 nM) or Dutch-mutant Aβ40 (E22Q, Kd > 12 nM). Because the two additional C-terminal hydrophobic residues (Ile41–Ala42) promote rapid β-sheet oligomerization, Aβ42 is transcytosed across the BBB roughly 2- to 3-fold more slowly than Aβ40.

1. Qian, H., Zhao, X., Cao, P., Lei, J., Yan, N., & Gong, X. (2017). "Structure of the human lipid exporter ABCA1." Cell, 169(7), 1228–1239.e10. https://doi.org/10.1016/j.cell.2017.05.020
2. Steinberg, S., Stefansson, H., Jonsson, T., et al. (2015). "Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease." Nature Genetics, 47(5), 445–447. https://doi.org/10.1038/ng.3246
3. De Roeck, A., Duchateau, L., Van Broeckhoven, C., & Sleegers, K. (2018). "An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease." Acta Neuropathologica, 135(6), 827–837. https://doi.org/10.1007/s00401-018-1841-z
4. Rauch, J. N., Luna, G., Guzman, E., et al. (2020). "LRP1 is a master regulator of tau uptake and spread." Nature, 580(7803), 381–385. https://doi.org/10.1038/s41586-020-2156-5